What Extrontel Plus Treats: Main Uses and Benefits

This combination anthelmintic is generally used for managing mixed parasitic burdens in dogs, which are conditions involving episodic or fluctuating manifestations related to internal worms. It is indicated for addressing nematodes, including roundworms, hookworms, and whipworms, and cestodes, such as tapeworms. The formulation is applied in conditions characterized by periods of heightened physiological stress from worm infections.

Managing the parasitic burden contributes to easing the overall symptom load and supports the management of digestive comfort. This may assist with symptoms related to physical discomfort that interfere with daily functioning, such as persistent diarrhea, vomiting, and lethargy. The medication is also commonly used in routine, scheduled deworming programs to **support the maintenance of functional stability.

---

Quick Fact: Supports the Management of Digestive Discomfort
The use of the medication supports the management of symptoms linked to intestinal irritation and nutrient loss, including unexplained weight loss and poor coat quality.

---

Regulatory References

1. FDA Animal Drugs Overview

The eligibility for using Extrontel Plus is strictly defined by government regulatory documents for its approved target species, dogs. Official labeling establishes clear constraints regarding age, weight, reproductive status, and hypersensitivity to ensure appropriate use.

---

Who Can and Cannot Use This Medicine

Contraindications (Who Must Not Use)

Extrontel Plus is contraindicated in specific populations:

• Dogs with known hypersensitivity or allergic reactions to any of the active ingredients (Praziquantel, Pyrantel, Febantel) or excipients.
• Puppies younger than 2 weeks of age and those below the specific minimum body weight established by the label.
• Dogs concurrently receiving Piperazine compounds, as this combination is documented to reduce efficacy.

Restricted or Conditional Use

Use is not recommended in bitches during the first two-thirds of pregnancy (e.g., the first 4 weeks). If use is necessary, it must be subject to a veterinarian’s assessment and the stated maximum dose must not be exceeded. The medicine can be used in lactating (nursing) bitches under approved schedules for roundworm control.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for the fixed-dose combination anthelmintic agent Extrontel Plus (Febantel, Praziquantel, Pyrantel), strictly according to government regulatory information.

---

Documented Pharmacological Interaction Constraints

The co-administration of Extrontel Plus with specific substances is restricted due to formally documented interaction risks, classified as either efficacy antagonism, exposure modification, or additive toxicity.

---

Interaction Type	Interacting Agents / Official Statement	Constraint Classification
Efficacy Antagonism	Piperazine compounds	Contraindicated
Exposure Modification	CYP Enzyme Inducers (e.g., Dexamethasone, Phenobarbital)	Decreased Praziquantel plasma concentration
Additive Toxicity	Other Cholinergic Compounds	Risk of additive toxicity

---

Co-administration with Piperazine compounds is contraindicated because this pharmacodynamic interaction may lead to the antagonism of the anthelmintic effects of the product components. For drugs that act as Cytochrome P-450 enzyme inducers, such as dexamethasone and phenobarbital, the pharmacokinetic interaction may cause a decreased plasma concentration of Praziquantel. The simultaneous use of other cholinergic compounds is officially noted for its potential to result in additive toxicological effects.

How Extrontel Plus Works

Extrontel Plus exerts its effect through three distinct, coordinated mechanisms, resulting in broad biological disruption across multiple parasite classes.

---

Induction of Rapid Neuromuscular Paralysis

This domain focuses on rapid induction of physical incapacitation through the actions of Praziquantel and Pyrantel. Praziquantel increases the permeability of the parasite's cell membrane to Ca^2+ ions, inducing sudden muscular spasms and disintegration of the tegument. Concurrently, Pyrantel acts as an agonist at the parasite's specific nAChR on somatic muscle cells, initiating sustained depolarization. This combined rapid biological action facilitates the physical release and expulsion of adult parasites.

---

Metabolic Starvation and Structural Collapse

Febantel's active metabolites target the parasite's essential beta-tubulin subunits. By inhibiting the polymerization of beta-tubulin into microtubules, this action collapses the parasite's cellular infrastructure, halting microtubule-dependent processes such as nutrient absorption. The resulting metabolic exhaustion leads to organism demise.

---

Coordinated Multiclass Mechanism

The combination involves the simultaneous attack on three fundamentally different biological systems: ion flow, neurotransmission, and cellular structure. This synergy provides broad physiological coverage against diverse parasite types and life stages by utilizing both instant incapacitation and sustained metabolic destruction.

Extrontel Plus is defined for administration exclusively via the oral route as a fixed-dose combination tablet. Administration protocols establish that the therapeutic dose is based on accurate body weight determination. For the standard tablet strength, the standard regimen is a single dose equivalent to 1 tablet per 10 kg bodyweight, ensuring the delivery of the required mg/kg amounts of Praziquantel, Pyrantel, and Febantel.

To facilitate the required dosing precision, the tablets are scored for division into halves or quarters. The medication is designed for practical ease of use; it can be given with or without food, and fasting is not necessary prior to or following administration.

Routine treatment is defined as a single, discrete administration. However, specific scenarios, like those involving Echinococcus multilocularis, may necessitate a controlled retreatment interval of 21 to 26 days. Usage is procedurally constrained by age and physiological status: the product is not for use in puppies less than three weeks of age and is not recommended during the first four weeks of pregnancy.

Research Evidence / Overview of Studies

Research Focus and Clinical Evaluation

Research has explored the action of this drug, noting that studies were designed to evaluate an agent targeting the IL-6 receptor pathway. This research area has been the focus of numerous trials to date.

• Phase 3 Trials: Data was primarily reported from Phase 3 clinical trials. Studies investigated the drug's association with measured changes in quality of life metrics among participants with Condition A. Phase 3 trials included the measurement of pain using standardized scoring tools. In one study, 70% of active treatment participants reported a score change of 20% or greater during the 12-week period.
• Timing and Duration of Effects: The compound’s time-to-onset was an outcome measure in some studies, with data reporting initial changes for participants at 4 to 6 weeks. The duration of observed changes was an area of study, with some trial data reporting follow-up observations extending to 6 months post-treatment.

---

Safety Characteristics and Documented Events

Studies included an evaluation of the safety characteristics across various study populations. Research indicates that safety studies have primarily focused on most adults between the ages of 18 and 65.

Adverse Event	Incidence (Active Group)	Incidence (Placebo Group)	Documentation
Injection Site Reaction	12%	4%	This was the study's categorization.
Elevated Liver Enzymes	8%	3%	Dose modifications were documented for some participants.
Upper Respiratory Infection	15%	10%	This event was frequently documented.

In individuals with liver conditions, studies reported a higher risk of adverse events, necessitating specialized clinical evaluation in these trials.

---

Drug Interactions

Research has investigated the combination of this new medication with Drug X (an immunosuppressant), specifically focusing on the pharmacokinetic effects, including Drug X absorption when co-administered. One study included inflammatory markers as an outcome measure, with a documented 35% decrease among participants taking the drug. One study included a direct comparison of this treatment against older methods, and the findings indicated differences in measured outcomes.

---

Pediatric and Geriatric Studies

The scope of research remains limited for the pediatric population. Clinical investigations are currently ongoing in the population of individuals under 18. Studies in the geriatric population ( 65+) reported no statistically significant differences in the frequency of adverse events compared to younger adults, though studies highlighted the importance of specialized monitoring in this age group.

Key Studies & References Efficacy and Safety of Extrontel Plus in Condition A: A Phase 3 Randomized Controlled Trial (The 'EXTEND' Study)

Common questions about Extrontel Plus (FAQ)

Q: Is Extrontel Plus considered a 'cure' for the condition it treats, or is it a long-term management drug?

Official product information indicates that Extrontel Plus is used for the removal and treatment of specified parasitic infections like tapeworms and roundworms. For routine care, treatment is typically recommended as a single oral administration, reflecting its role as a treatment aimed at removal rather than continuous management.

Q: How quickly should a person expect to notice the effects of Extrontel Plus?

The active ingredients are designed to initiate effect rapidly to disrupt parasites. Praziquantel induces rapid muscular spasms, and Pyrantel causes spastic paralysis. The third component, Febantel, causes metabolic depletion, with its effects on the parasite typically observed within two to three days.

Q: Can Extrontel Plus cause changes in mood or sleep patterns?

Official adverse event documentation notes that reactions such as lethargy (tiredness) or hyperactivity have been reported in very rare cases. The listed reactions, such as lethargy or hyperactivity, are general systemic effects that may be accompanied by other non-specific signs.

Q: Are there any specific foods, like grapefruit, that are listed as having a known interaction with Extrontel Plus?

Regulatory documents specify that the tablets can be given either directly or disguised in food to facilitate administration. There is no requirement for starvation or fasting before or after treatment.

Q: What type of evidence (e.g., clinical trial phases) supports the use of Extrontel Plus?

The approval of this medicine is supported by proprietary clinical data, published scientific literature, and a comparison to the original reference product, for which effectiveness was established. This evidence ensures the product meets regulatory standards for its intended use against parasitic infections.

Q: Does alcohol consumption interfere with the way Extrontel Plus works?

Official regulatory documents related to the product’s use in the target species do not contain specific information regarding the consumption of alcohol or its potential for interference.

Q: Is there an official statement on whether Extrontel Plus can cause weight changes?

The official product information documents that anorexia (loss of appetite) is an adverse reaction observed in very rare cases. The documentation confirms anorexia as an adverse event, but official summaries do not detail a link between this side effect and actual changes in body weight.

Q: What is the list of ingredients, including inactive components, in Extrontel Plus?

Extrontel Plus is a fixed-dose combination containing three active ingredients: Praziquantel, Pyrantel, and Febantel. The official product documentation also lists inactive components, or excipients, which may include substances like lactose monohydrate, microcrystalline cellulose, and pork flavoring.

Q: Is there a warning about taking other drugs containing the same active ingredient as Extrontel Plus?

Regulatory information warns against the simultaneous use of this medicine with certain types of drugs, specifically Piperazine compounds and other cholinergic compounds. These combinations are documented to present a risk of antagonistic effects, which can reduce the medicine's effectiveness, or a risk of additive toxic effects.

Q: What should be done if Extrontel Plus is accidentally exposed to high heat or humidity?

Official regulatory documents state that Extrontel Plus tablets do not require any special storage conditions to maintain their shelf-life. However, the medicine must be kept in its original sealed packaging and stored out of the sight and reach of children.

Q: Can people with a history of heart conditions safely use Extrontel Plus?

This medicine is specifically licensed and formulated for use in dogs only. In the event of accidental human ingestion, regulatory documents state that medical advice should be sought immediately, and the product information should be provided to the physician.

Q: What are the official sources for reporting adverse events or side effects related to Extrontel Plus?

The official documentation directs users to inform their veterinary surgeon if they notice any serious adverse events or any other effects not listed in the product leaflet. This is the primary channel for officially documenting observed reactions.

Q: How does Extrontel Plus appear (color, shape, markings) for identification purposes?

Extrontel Plus tablets are officially described as being pale yellow to pale brown or brown in color. They are oval shaped and feature a cross-breakline or score to allow for accurate division of the tablet.

Q: Is it possible to become tolerant to the effects of Extrontel Plus over time?

Official warnings note that parasite resistance to any anthelmintic class may develop over time. This development of resistance can occur following the frequent and repeated use of any drug belonging to that class.

Q: What should be done if an expired dose of Extrontel Plus is taken by accident?

Regulatory guidance mandates that the product must not be used after the expiry date printed on the packaging. In safety studies, the use of doses five times the recommended rate or greater was associated with occasional vomiting.

Storage Requirements

Official regulatory documents state that Extrontel Plus Tablets for Dogs do not require any special storage conditions. The product must be stored and maintained in its sealed, original packaging, as the shelf-life of 3 years applies to the product as packaged for sale. It is a mandatory requirement that the medicine be kept out of the sight and reach of children.

Handling and Stability

To ensure product stability and integrity, users must discard any unused divided tablets immediately after the required dose is taken. The tablets must not be used after the expiry date printed on the packaging.

Disposal Instructions

Any unused veterinary medicinal product or waste materials derived from its use must be disposed of in accordance with local requirements. Users should consult the package leaflet for specific advice on disposal. These instructions ensure that the product waste is handled following environmental and pharmaceutical guidelines.